News & Updates

$Zoledronate offers protection against fractures for up to 3.5 years$

Zoledronate offers protection against fractures for up to 3.5 years

12 Mar 2024

Treatment with zoledronate leads to reduced fracture rates, with the protective benefit persisting for 1.5 to 3.5 years after the final dose, as reported in the extension phase of a study.

Zoledronate offers protection against fractures for up to 3.5 years

12 Mar 2024

$Benralizumab noninferior to mepolizumab for relapsing, refractory EGPA$

Benralizumab noninferior to mepolizumab for relapsing, refractory EGPA

10 Mar 2024 by

Benralizumab compares favourably with mepolizumab for inducing remission in adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), as shown in the results of the head-to-head phase III MANDARA trial.

Benralizumab noninferior to mepolizumab for relapsing, refractory EGPA

10 Mar 2024

Severe COVID-19 rare in PrEP-treated SARDs patients

08 Mar 2024 by

Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.

Severe COVID-19 rare in PrEP-treated SARDs patients

08 Mar 2024

Denosumab carries severe hypocalcaemia risk in older female dialysis-dependent patients

07 Mar 2024

In the treatment of osteoporosis among older women who are dialysis-dependent, the use of denosumab appears to result in a much higher incidence of severe and very severe hypocalcaemia when compared with oral bisphosphonates, according to a retrospective cohort study.

Denosumab carries severe hypocalcaemia risk in older female dialysis-dependent patients

07 Mar 2024

Original New Drug Application Approvals by US FDA (16-29 February 2024)

06 Mar 2024

New drug applications approved by US FDA as of 16-29 February 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-29 February 2024)

06 Mar 2024

Denosumab for osteoporosis shows potential for lowering diabetes risk

02 Mar 2024 by

Treatment with denosumab in people with osteoporosis confers a protective effect against the risk of developing diabetes, according to the results of a propensity score–matched cohort study from Taiwan.